BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 08, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Horizant gabapentin enacarbil regulatory update

FDA accepted for review a response from GlaxoSmithKline to a February complete response letter for Horizant gabapentin enacarbil (XP13512, GSK1838262) extended-release tablets to treat moderate to severe primary restless legs syndrome (RLS). FDA designated the response as a Class 2 resubmission and set a...

Read the full 196 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >